Cat. No. 2432
Alternative Name: BL 4162A
Chemical Name: 6,7-Dichloro-1,5-dihydroimidazo[2,1
Biological ActivityPotent type III phosphodiesterase (PDE3) inhibitor (IC50 = 36 nM). Inhibits platelet aggregation and produces potent thrombocytopenic effects via inhibition of megakaryocyte maturation.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Wang et al (2005) Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures. Br.J.Pharmacol. 146 324. PMID: 16041400.
Mazur et al (1992) Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. Blood 79 1931. PMID: 1562721.
Gillespie (1988) Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity. Biochem.Pharmacol. 37 2866. PMID: 2456068.
If you know of a relevant reference for Anagrelide hydrochloride please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Anagrelide hydrochloride from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Anagrelide hydrochloride, supplier, Potent, PDE3, inhibitors, inhibits, Phosphodiesterases, BL4162A, Tocris Bioscience, Phosphodiesterase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Fluorometric CYP450 substrateGaleterone
CYP17 inhibitor; also androgen receptor antagonistPF 04449613
Potent PDE9 inhibitor; brain penetrant
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.